Catalog No.
DHC90740
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG
Clonality
Monoclonal
Target
B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P11836
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
TRU015, TRU 015, TRU-015
Clone ID
TRU015
Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia., PMID:23252565
New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies., PMID:21090841
TRU-015, a fusion protein derived from an anti-CD20 antibody, for the treatment of rheumatoid arthritis., PMID:20140823
[Novel B-cell directed strategies for the treatment of rheumatic diseases]., PMID:19513729
CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells., PMID:19351771
Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study., PMID:19014836
Emerging therapeutics for rheumatoid arthritis., PMID:18937634
Gateways to clinical trials., PMID:18560631
New approaches of B-cell-directed therapy: beyond rituximab., PMID:18388516
Gateways to clinical trials., PMID:17440629
For research use only. Not for human or drug use.
